The fire under GlaxoSmithKline’s Emma Walmsley grows as another well-known activist investor grabs its pitchfork — report

Bluebell Capital Partners, a proxy brawler fresh off a campaign to oust global food giant Danone’s CEO and most of its board of directors, has bought a stake in UK drugmaker GlaxoSmithKline with its eyes trained directly on Emma Walmsley, the Financial Times reported Wednesday.


Click to view original post